Delpor to Tackle Opioid Use Disorder with $5.7 million NIH HEAL Grant Award for the Development of a Once-Yearly Naltrexone Therapy to Prevent Relapses
Company to expand the use of its PROZOR implant technology by building on the success with its lead antipsychotic program Upon successful completion of the grant’s initial phase, Delpor may [...]
Delpor Awarded $1.5 million NIH Grant for Exenatide Implant for the Treatment of Type 2 Diabetes
The NIDDK continues to fund Delpor’s efforts to utilize its NANOPORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion SAN FRANCISCO, [...]
Delpor Announces Issuance of US Patent Covering its Novel Implantable Device for the Long-Term Delivery of Antipsychotics and other Drugs
The patent covers Delpor’s PROZORTM technology which enables the sustained release of antipsychotics and other molecules from a matchstick-size implant device. Delpor has several products in development, including a 6-month formulation [...]
Delpor Selected by the NIH to Exhibit its Technology at the 2017 BIO International Convention
Delpor will be part of the Innovation Zone, a high profile 6,000 square foot exhibit space dedicated to showcasing 60 NIH and 20 NSF SBIR/STTR awardees. Delpor expects to meet [...]
Delpor Awarded NIH Grant for 3-month Olanzapine Implant for the treatment of Schizophrenia
The NIMH funds Delpor’s efforts to utilize its PROZORTM technology in developing a matchstick-size subcutaneous implant device capable of delivering olanzapine for 3 months through passive diffusion. The product is expected [...]
Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin. SAN FRANCISCO, CA, April 23, [...]